MDS 2022 | Update on OCEAN and OASIS: Opicapone for pain & sleep disorders in PD
K. Ray-Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, shares an update on two clinical trials exploring the addition of opicapone to levodopa to address non-motor symptoms. The randomized, double-blind placebo-controlled OCEAN study (OpiCapone Effect on motor fluctuations and pAiN; NCT04986982) investigating opicapone for modulating pain in Parkinson’s disease is currently recruiting, and results are eagerly awaited. The OASIS study (OpicApone Sleep dISorder; NCT04986995) will evaluate the effects of opicapone on sleep disorders in Parkinson’s disease patients. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
There are two studies where this concept of adding opicapone to levodopa and addressing non-motor symptoms are being explored. The first and foremost is a double-blind, randomized placebo-controlled study, which is called the OCEAN study, which is recruiting from 140 patients from about 30 countries. 40 patients have already been recruited.
And this study will look at the effect of addition of opicapone versus placebo, mainly on pain using the King’s Parkinson Pain Scale on fluctuation-related pain...
There are two studies where this concept of adding opicapone to levodopa and addressing non-motor symptoms are being explored. The first and foremost is a double-blind, randomized placebo-controlled study, which is called the OCEAN study, which is recruiting from 140 patients from about 30 countries. 40 patients have already been recruited.
And this study will look at the effect of addition of opicapone versus placebo, mainly on pain using the King’s Parkinson Pain Scale on fluctuation-related pain. But other domains of pain, non-motor scale, motor function, and quality of life will also be addressed. We look forward to the data from this scale with great interest because this would be one of the first studies to give us level one evidence about the efficacy of opicapone to treat this non-motor fluctuation, particularly pain.
OASIS is another study where opicapone is being added to levodopa to see its effect on sleep as measured by the Parkinson’s Disease Sleep Scale two. And this is an open-label study, Phase IV open-label, which will recruit 30 patients altogether and has also now opened.
Read more...
